Core Viewpoint - The Invesco S&P MidCap Value with Momentum ETF (XMVM) is designed to provide broad exposure to the Mid Cap Value segment of the US equity market, with assets over $268.40 million, making it an average-sized ETF in this category [1] Group 1: Mid Cap Value Characteristics - Mid cap companies have market capitalizations between $2 billion and $10 billion, offering a balance of growth potential and stability compared to large and small cap companies [2] - Value stocks typically have lower price-to-earnings and price-to-book ratios, but also lower sales and earnings growth rates; historically, value stocks have outperformed growth stocks in most markets [3] Group 2: Costs and Performance - The ETF has an annual operating expense ratio of 0.39% and a 12-month trailing dividend yield of 2.07%, which is competitive within its peer group [4] - XMVM aims to match the performance of the S&P MIDCAP 400 HIGH MOMENTUM VALUE INDEX, having gained approximately 5.31% year-to-date and 10.17% over the past year as of July 15, 2025 [7] Group 3: Sector Exposure and Holdings - The ETF has a significant allocation to the Financials sector, comprising about 46.60% of the portfolio, with Consumer Discretionary and Industrials following [5] - Avnet Inc (AVT) represents about 2.77% of total assets, with the top 10 holdings accounting for approximately 21.15% of total assets under management [6] Group 4: Risk and Alternatives - XMVM has a beta of 1.08 and a standard deviation of 21.28% over the trailing three-year period, indicating effective diversification of company-specific risk with around 80 holdings [8] - Alternatives to XMVM include the iShares Russell Mid-Cap Value ETF (IWS) and the Vanguard Mid-Cap Value ETF (VOE), which have larger asset bases and lower expense ratios [11]

Group 1 - The stock market is reaching new highs, prompting a shift towards value stocks, particularly focusing on "fallen angels" that have lost popularity [1] - The analyst has extensive experience in technology companies, having worked on Wall Street and in Silicon Valley, and has been advising seed-round startups [1] - The analyst has been contributing to Seeking Alpha since 2017 and has been featured in various web publications, with articles syndicated to popular trading apps like Robinhood [1]

Market Outlook - The market is on pace to open at records, with a generally bullish outlook on stocks [1] - Diversification is key, with a preference for owning growthier value and "garbier" growth stocks, focusing on dividend growers rather than just payers [2] - The US market is favored, with an overweight position, but exposure to developed international and emerging markets is maintained [2] - Equities are viewed favorably, with a suggestion to overweight equities and have some exposure to fixed income for traditional diversification [3] Sector Focus - Consumer discretionary is a sector of interest, highlighted by Nike's earnings [4] - Despite Nike beating low earnings expectations, issues like a billion-dollar tariff expense and supply chain problems are flagged, with sales expected to be lower [5] - The American consumer is seen as remarkably resilient due to strong job market, supporting the consumer discretionary sector [6] Monetary Policy & Risk - Concerns about a "shadow Fed president" are considered less significant, as diverse opinions already exist within the Federal Reserve [7] - The Federal Reserve's independence is crucial, and potential commentary from other channels should be viewed in light of Jerome Powell's stance [8] - Expectation of rate cuts, potentially starting in September and with another 100 basis points (1%) removed by the end of the year from the monetary policy elevation since March 2022 [8][9]

Group 1 - The Conservative Income Portfolio targets value stocks with high margins of safety and aims to reduce volatility through well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - Sunbelt is noted to be lagging behind other regions in terms of fundamentals [1] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and focusing on capital preservation [2] - The Conservative Income Portfolio is run in partnership with Preferred Stock Trader and features two income-generating portfolios along with a bond ladder [2]

Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Kamada (KMDA) and Acadia Pharmaceuticals (ACAD) for potential value investments [1] - A strong Zacks Rank combined with a high Value category grade is identified as an effective strategy for finding value stocks [2] Valuation Metrics - Kamada has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Acadia Pharmaceuticals has a Zacks Rank of 3 (Hold) [3] - Kamada's forward P/E ratio is 21.64, significantly lower than Acadia's forward P/E of 45.77, suggesting Kamada may be undervalued [5] - Kamada's PEG ratio is 0.87, compared to Acadia's PEG ratio of 4.87, indicating better expected earnings growth relative to its price [5] - Kamada's P/B ratio is 1.63, while Acadia's P/B ratio is 4.99, further supporting Kamada's valuation advantage [6] - Based on these metrics, Kamada earns a Value grade of A, while Acadia receives a Value grade of C, positioning Kamada as the superior value option [6]

Core Viewpoint - The comparison between Carnival (CCL) and Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) indicates that CCL currently offers better value for investors based on various financial metrics and rankings [1][3][7]. Valuation Metrics - CCL has a forward P/E ratio of 12.63, while ATAT has a forward P/E of 20.03, suggesting that CCL is more attractively priced [5]. - The PEG ratio for CCL is 0.55, compared to ATAT's PEG ratio of 0.92, indicating that CCL may offer better value relative to its expected earnings growth [5]. - CCL's P/B ratio stands at 2.99, significantly lower than ATAT's P/B ratio of 9.91, further supporting the notion that CCL is undervalued [6]. Zacks Rank and Value Grades - CCL holds a Zacks Rank of 2 (Buy), while ATAT has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for CCL [3][7]. - CCL has a Value grade of A, whereas ATAT has a Value grade of C, reflecting CCL's superior valuation metrics [6].

Group 1 - The stock market appears complacent regarding long-term macro risks, including potential recessionary impacts from tariffs and signs of strain in the bond market [1] - Emphasis is placed on value stocks over growth stocks in the current market environment [1] - Gary Alexander has extensive experience in technology companies and has been a contributor to Seeking Alpha since 2017, providing insights into industry trends [1]

Core Insights - The article emphasizes the importance of innovation and disruption in the financial sector, particularly focusing on high-tech and early growth companies [1] Group 1: Company Insights - The article highlights the potential investment opportunities in growth buyouts and value stocks, indicating a favorable outlook for investors in these areas [1] Group 2: Industry Trends - There is a strong focus on the pace of technological advancements and their impact on investment strategies, suggesting that companies that adapt quickly to these changes may offer significant returns [1]

Core Viewpoint - CVS Health is currently viewed as a more attractive option for value investors compared to Danaher based on various valuation metrics and earnings outlook [3][7]. Valuation Metrics - CVS Health has a forward P/E ratio of 9.98, significantly lower than Danaher's forward P/E of 23.97 [5]. - CVS has a PEG ratio of 0.87, while Danaher has a PEG ratio of 2.54, indicating CVS is expected to grow earnings at a more favorable rate relative to its price [5]. - CVS's P/B ratio stands at 1, compared to Danaher's P/B of 2.60, suggesting CVS is more undervalued in terms of its book value [6]. Earnings Outlook - CVS Health has a Zacks Rank of 2 (Buy), indicating an improving earnings outlook, while Danaher holds a Zacks Rank of 3 (Hold) [3][7]. - The positive revisions to CVS's earnings estimates contribute to its favorable position in the Zacks Rank model [3][7]. Value Grades - CVS has received a Value grade of A, while Danaher has a Value grade of D, further supporting the conclusion that CVS is the superior value option at this time [6].

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...